Insight, China's Pharmaceutical Industry

Company Drug

Sanofi’s Venglustat Wins FDA Breakthrough Therapy Designation – Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms

Sanofi (NASDAQ: SNY) announced that venglustat received Breakthrough Therapy Designation (BTD) from the U.S. Food...

Company Deals

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

Fineline Cube Mar 19, 2026

Sipai Health Technology Co., Ltd. (HKG: 0314), operating as Medbanks, announced the acquisition of 100%...

Company Drug

TransThera Sciences Doses First Patient in Phase II Tinengotinib Combination Study – Multi-Kinase Inhibitor Plus Fulvestrant Targets HR+/HER2- Breast Cancer

Fineline Cube Mar 19, 2026

TransThera Sciences (Nanjing), Inc. (HKG: 2617) announced first patient dosing in a Phase II clinical...

Company Deals

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Fineline Cube Mar 19, 2026

Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751...

Company Deals

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Fineline Cube Mar 19, 2026

Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ:...

Policy / Regulatory

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Fineline Cube Mar 19, 2026

The US Food and Drug Administration (FDA) has advanced its “Roadmap to Reducing Animal Testing...

Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Fineline Cube Mar 18, 2026

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China’s...

Company Deals

Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug

Fineline Cube Mar 18, 2026

Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for...

Company Deals

Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets

Fineline Cube Mar 18, 2026

Shanghai Ark Biopharmaceutical Co., Ltd. has submitted an initial public offering (IPO) filing to the...

Company Deals

Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform

Fineline Cube Mar 18, 2026

Everest Medicines Limited (HKG: 1952) announced the signing of a letter of intent to acquire...

Company Drug

Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer

Fineline Cube Mar 18, 2026

Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating...

Company Drug

AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer – Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial

Fineline Cube Mar 18, 2026

AstraZeneca PLC (NASDAQ: AZN) announced European Union marketing approval for Imfinzi (durvalumab) in combination with...

Company Deals

Kintor Pharma Partners with Chicmax to Accelerate KT‑939 Commercialization – Active Cosmetic Ingredient Targets Whitening Market

Fineline Cube Mar 18, 2026

Kintor Pharmaceutical Limited (HKG: 9939) has entered into a strategic partnership with Shanghai Shangmei Cosmetics...

Company Drug

UniXell Bio Secures FDA Approval for UX‑GIP001 – First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials

Fineline Cube Mar 18, 2026

Shanghai UniXell Biotechnology Co., Ltd. announced that its iPSC‑derived allogeneic cell therapy UX‑GIP001 has received...

Others

Simcere Pharma Reports Positive SIM0237 Phase I/II Data – 80% CR Rate in BCG‑Unresponsive Bladder Cancer

Fineline Cube Mar 18, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) announced positive Phase I/II results for SIM0237, its PD‑L1/IL‑15...

Company Medical Device

Bio-heart Bio Expands Iberis RDN Registration to Thailand – World’s Only Dual‑Access Renal Denervation System

Fineline Cube Mar 18, 2026

Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced Thailand regulatory registration of its Iberis...

Company Drug

Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect – Self‑Pay Pricing for Dual‑Target Obesity Drug

Fineline Cube Mar 18, 2026

Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single‑patient‑use Zepbound...

Company Medical Device

Peijia Medical Secures First FDA 510(k) Clearance for DCwire Micro Guidewire – US Market Entry Milestone

Fineline Cube Mar 18, 2026

Peijia Medical Ltd (HKG: 9996) announced that its DCwire micro guidewire has received 510(k) clearance...

Others

Shanghai Pharmaceuticals and Henlius Forge Strategic Alliance – Hospital Market Expansion and Global Commercial Collaboration Targeted

Fineline Cube Mar 17, 2026

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH; HKG: 2607, SHA: 601607) and Henlius (HKG: 2696) announced...

Company Drug

Henlius Wins NMPA Approval for HLX07 Combination Trial – Anti-EGFR Biologic Plus Serplulimab Targets Squamous NSCLC

Fineline Cube Mar 17, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that subsidiary Shanghai Henlius...

Insight, China's Pharmaceutical Industry

Sihuan Pharmaceutical and dProtein Biotechnology Form AI-Powered Medical Aesthetics Joint Venture

Salvectors Receives NMPA Clinical Approval for YB1-X7, World’s First Oncolytic Salmonella Therapy for Advanced Solid Tumors

Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico

Genrix Bio Licenses BCMA×CD3 Bispecific Velinotamig to Fosun’s Yaopharma for Greater China in $268M Deal

Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Sanofi’s Venglustat Wins FDA Breakthrough Therapy Designation – Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

TransThera Sciences Doses First Patient in Phase II Tinengotinib Combination Study – Multi-Kinase Inhibitor Plus Fulvestrant Targets HR+/HER2- Breast Cancer

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug

Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets

Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform

Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer

AstraZeneca Secures EU Approval for Imfinzi in Gastric Cancer – Perioperative Regimen Cuts Death Risk 22% in MATTERHORN Trial

Kintor Pharma Partners with Chicmax to Accelerate KT‑939 Commercialization – Active Cosmetic Ingredient Targets Whitening Market

UniXell Bio Secures FDA Approval for UX‑GIP001 – First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials

Simcere Pharma Reports Positive SIM0237 Phase I/II Data – 80% CR Rate in BCG‑Unresponsive Bladder Cancer

Bio-heart Bio Expands Iberis RDN Registration to Thailand – World’s Only Dual‑Access Renal Denervation System

Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect – Self‑Pay Pricing for Dual‑Target Obesity Drug

Peijia Medical Secures First FDA 510(k) Clearance for DCwire Micro Guidewire – US Market Entry Milestone

Shanghai Pharmaceuticals and Henlius Forge Strategic Alliance – Hospital Market Expansion and Global Commercial Collaboration Targeted

Henlius Wins NMPA Approval for HLX07 Combination Trial – Anti-EGFR Biologic Plus Serplulimab Targets Squamous NSCLC

You Missed

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Northland Biotech’s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers

AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome